Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OWCP 5.00 LOOK AT THE BIG PICTURE CATALYSTS GALORE !!!!!!!!!!!!!!!
Surf 100% correct. Owcp future cures coming !!!!
Owcp. Future of psorasis cure naturally. !!!
Owcp future of medicine
Owcp. 8 patents the future of. Medicine. !!!!!
Owcp patents for psorasis & mylenoma. Life changing for the better of all !!!!!!
Kim you are correct. Now. They can migrate to another exchange
SUNRISE, FL / ACCESSWIRE / January 23, 2017 / US STEM CELL, Inc. (OTCQB: USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients, is pleased to announce our newest publication by our Chief Scientific Officer, Kristin Comella.
"Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease" was published in the January volume of the Journal of Translational Medicine. The study focused on the implantation of stromal vascular fraction (SVF) in patients suffering from degenerative disc disease. Patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue from the abdomen. The fat was separated to isolate the SVF and the cells were delivered directly into the damaged discs. Patients were monitored for a period of 6 months post-treatment, noting considerable decreases in pain and increases in flexion. A copy of the paper can be accessed on pubmed: https://www.ncbi.nlm.nih.gov/pubmed/28086781.
Ms. Comella's previous paper, "Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy," was released in the Journal of Translational Medicine's June 2016 edition. Using the same procedure, chronic ischemic cardiomyopathy patients were evaluated after SVF injection and able to walk more than 80 additional meters 3 to 6 months after treatment. A copy of the paper can be accessed on pubmed: https://www.ncbi.nlm.nih.gov/pubmed/27255774.
At U.S. Stem Cell, Inc., we are committed to new technological advancements and therapies that give a renewed sense of hope to patients with degenerative diseases. SVF is the latest therapy in a long line of successful treatments we have pioneered. Ms. Comella plans to continue her work with SVF, which has consistently repeated its strong safety profile and success in treating patients.
About U.S. Stem Cell, Inc.
US Stem cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development, and commercialization of cell based therapeutics that prevent, treat, or cure disease by repairing and replacing damaged or aged tissue, cells, and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.
Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities, as they do today for our general business operations. We believe the combination of our own therapeutics pipeline, combined with our revenue generating capabilities, provides the Company with a unique opportunity for growth and a pathway to profitability.
Forward-Looking Statements:
Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue," or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.
Media Contact:
U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 954.835.1500
usstemcell@us-stemcell.com
SOURCE: U.S. Stem Cell, Inc.
© Copyright © 2017 Accesswire. All rights reserved.
SUNRISE, FL / ACCESSWIRE / January 23, 2017 / US STEM CELL, Inc. (OTCQB: USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients, is pleased to announce our newest publication by our Chief Scientific Officer, Kristin Comella.
"Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease" was published in the January volume of the Journal of Translational Medicine. The study focused on the implantation of stromal vascular fraction (SVF) in patients suffering from degenerative disc disease. Patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue from the abdomen. The fat was separated to isolate the SVF and the cells were delivered directly into the damaged discs. Patients were monitored for a period of 6 months post-treatment, noting considerable decreases in pain and increases in flexion. A copy of the paper can be accessed on pubmed: https://www.ncbi.nlm.nih.gov/pubmed/28086781.
Ms. Comella's previous paper, "Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy," was released in the Journal of Translational Medicine's June 2016 edition. Using the same procedure, chronic ischemic cardiomyopathy patients were evaluated after SVF injection and able to walk more than 80 additional meters 3 to 6 months after treatment. A copy of the paper can be accessed on pubmed: https://www.ncbi.nlm.nih.gov/pubmed/27255774.
At U.S. Stem Cell, Inc., we are committed to new technological advancements and therapies that give a renewed sense of hope to patients with degenerative diseases. SVF is the latest therapy in a long line of successful treatments we have pioneered. Ms. Comella plans to continue her work with SVF, which has consistently repeated its strong safety profile and success in treating patients.
About U.S. Stem Cell, Inc.
US Stem cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development, and commercialization of cell based therapeutics that prevent, treat, or cure disease by repairing and replacing damaged or aged tissue, cells, and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.
Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities, as they do today for our general business operations. We believe the combination of our own therapeutics pipeline, combined with our revenue generating capabilities, provides the Company with a unique opportunity for growth and a pathway to profitability.
Forward-Looking Statements:
Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue," or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.
Media Contact:
U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 954.835.1500
usstemcell@us-stemcell.com
SOURCE: U.S. Stem Cell, Inc.
© Copyright © 2017 Accesswire. All rights reserved.
Got in last week at .0075. Try to get in sooner but I couldn't. Go. Usrm. !!!
Ppch cancer patent.us. Fda granted.
Huge ah buys. Things happening. I've been here since October and this thing has done this all the time every other week it's super high and then goes all the way back down 50% and I'm just here for longevity
588k. Investor after hours. Go. Owcp
Owcp oversold. 60% success remission rate mylenoma. !!!!!
Usrm May merge with PPCH is they have a patent to kill cancer stem cells. Go. Usrm. Ppch. Check the Propanc website for details
7 months no ticker or name change. Ask yourself why ????
Trump Fda. Speed up. Process. Propanc. Works
28 day results are a tremendous catalyst for ppch.
Fda 80 % of all cancer patent ppch is advancing medicine !!!!!
Owcp future of medicine
First in man study gonna knock your sox off. Go. Ppch. !!!
Blue skies. Go Owcp
Go Owcp !!!! Been here since October. Going to be here forever
It did I was there.
Great news Owcp. !!!!!!
Strong hands grabbing shares of a great company
Ppch patent for 80% of all cancers. From. Fda. !!!!
Ppch has fda patent for solid tumors. 80% of all cancers
Fda grants ppch Cancer. patent solid tumors which are 80% of all cancers
Owcp. In the place to be long & strong
Owcp future of medicine. Go OWCP. !!!
Grants partnership in the works. Go ppch
Phase 2a. news coming Thursday
Owcp holding since sept 30tth. Go owcp. !!!
Owcp. Great co. !
Ppch forefront of medicine. Go ppch
Halting Cancer Cells’ Ability to Invade and Metastasize
PRP, our lead candidate, controls cancer cell migration, inhibits tumor blood vessel formation and triggers the cell’s death.
OTC markets had Kaly therapeutics info under this Kaly marine companies.
Huge News Thurs. they. Bought. Canabis. Research. Co. 2a. Results. Go. Kaly